Get started

Investing

MERCADOLIBRE ($MELI) SOARS IN Q4—E-COMMERCE & FINTECH SHINE MERCADOLIBRE ( NASDAQ:MELI ) SOARS IN Q4—E-COMMERCE & FINTECH SHINE (1/9) Good evening, Tradingview! MercadoLibre ( NASDAQ:MELI ) is sizzling—Q4 revenue up 37%, a $ 6.1B haul 📈🔥. Fintech and e-commerce fuel a 33% surge—let’s unpack this Latin dynamo! 🚀 (2/9) – REVENUE RUSH • Q4 Take: $ 6.1B—37% leap, tops $ 5.9B est. 💥 • EPS: $ 12.61—blasts past $ 7.94 hopes 📊 • Net Income: $ 639M—beats $ 402M dreams NASDAQ:MELI ’s humming—growth’s got zing! (3/9) – BIG MOVES • GMV: $ 14.5B—56% jump FX-neutral 🌍 • Payments: $ 58.9B TPV—49% up 🚗 • Credit Boom: $ 6.6B—74% growth 🌟 NASDAQ:MELI ’s flexing muscle—full throttle! (4/9) – MARKET VIBE • P/E: ~60—above Amazon’s 40, PDD’s 20 📈 • Growth: 37% smokes peers’ 10% • Targets: 2,400−3,000—10-38% upside 🌍 Premium price—worth the juice? (5/9) – RISKS ON DECK • FX Woes: Brazil, Mexico currencies wobble ⚠️ • Comp: Amazon, locals eye the prize 🏛️ • Rates: $ 6.6B credit—defaults lurk? 📉 Hot run—can it dodge the heat? (6/9) – SWOT: STRENGTHS • E-comm: $ 14.5B GMV—LatAm king 🌟 • Fintech: $ 58.9B TPV—Pago’s gold 🔍 • Logistics: 6 new centers—zippy edge 🚦📉 NASDAQ:MELI ’s a double-threat dynamo! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: High P/E, FX swings 💸 • Opportunities: Ad bucks, untapped markets 🌍 Can NASDAQ:MELI zap past the bumps? (8/9) – NASDAQ:MELI ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—$ 3,000 in sight. 2️⃣ Neutral—Growth’s hot, risks hover. 3️⃣ Bearish—FX bites back. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:MELI ’s $ 6.1B Q4 and fintech flex spark buzz—$ 14.5B GMV shines 🌍🪙. High P/E, but growth rules—champ or chase?
NASDAQ:MELI
by DCAChampion
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH (1/9) Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀 (2/9) – REVENUE RUSH • Q4 Haul: $ 2.91B—16% jump from last year 💥 • Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊 • ‘25 Outlook: $11.75-$ 12B—6-9% growth NYSE:CF keeps humming—newbies add zest! (3/9) – BIG WINS • Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍 • Alyftrek: CF drug for 6+—ships now 🚗 • Cash: $11.2B—loaded for action 🌟 NASDAQ:VRTX storms pain—CF stays golden! (4/9) – SECTOR CHECK • Valuation: 11x sales—above 9x avg 📈 • Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium? • Growth: 12% beats biotech’s 5-7% 🌍 NASDAQ:VRTX flexes—value or stretch? (5/9) – RISKS ON TAP • Payers: Journavx needs coverage—hiccups? ⚠️ • Trikafta: 93% of sales—big lean 🏛️ • Comp: Pain rivals, CF safe—for now 📉 Hot streak—can it dodge the bumps? (6/9) – SWOT: STRENGTHS • CF King: Trikafta, Alyftrek lock it in 🌟 • Pain Play: Journavx eyes $ 4B peak 🔍 • Cash: $11.2B—war chest ready 🚦 NASDAQ:VRTX ’s got muscle and moolah! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Trikafta reliance—eggs in one basket 💸 • Opportunities: Casgevy rolls, pain grows 🌍 Can NASDAQ:VRTX zap past the risks? (8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—Pain pays off big. 2️⃣ Neutral—Solid, but risks linger. 3️⃣ Bearish—Growth hits a wall. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
NASDAQ:VRTXLong
by DCAChampion
CELSIUS ($CELH) ZAPS UP 33%—Q4 & ALANI NU IGNITE BUZZCELSIUS ( NASDAQ:CELH ) ZAPS UP 33%—Q4 & ALANI NU IGNITE BUZZ (1/9) Good evening, Tradingview! Celsius Holdings ( NASDAQ:CELH ) just surged 33%—Q4 earnings and a $1.65B Alani Nu buyout lit the fuse 📈🔥. Energy drink market’s buzzing—let’s unpack this jolt! 🚀 (2/9) – EARNINGS SNAP • Q4 Revenue: $332M, topped $329M expected 💥 • Margin: Jumped to 50.2%—beats 47.1% hopes 📊 • EPS: $0.14, above $0.11—solid grit Growth slowed, but NASDAQ:CELH flexed resilience! (3/9) – ALANI NU DEAL • Price: $1.65B—$1.275B cash, $500M stock 🌍 • Alani’s Pull: $595M ‘24 sales, 78% growth 🚗 • Combo: 16% energy drink share—$ 2B ‘25 goal 🌟 NASDAQ:CELH snags a rival—big playtime! (4/9) – MARKET VIBE • Surge: 33% to $33-$35—shorts burned 📈 • Vs. Peers: 6x sales, below 9x avg—value? • X Hype: “Top gainer”—bulls cheer 🌍 NASDAQ:CELH heats up—bargain or buzz? (5/9) – RISKS IN SIGHT • Overlap: Alani vs. CELH—cannibal clash? ⚠️ • Slowdown: North Am. down 6%—Pepsi hiccups 🏛️ • Comp: Rivals eye shelf space—tight race 📉 Hot move, but bumps lurk ahead! (6/9) – SWOT: STRENGTHS • Deal: $1.65B Alani—growth rocket 🌟 • Margin: 50.2%—profit punch 🔍 • Global: 39% intl. leap—worldwide zip 🚦 NASDAQ:CELH ’s firing on all cylinders! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Q4 dip, overlap risks 💸 • Opportunities: $ 2B sales, $50M synergies 🌍 Can NASDAQ:CELH juice up the doubters? (8/9) – NASDAQ:CELH ’s 33% zap—what’s your vibe? 1️⃣ Bullish—$40+ in sight. 2️⃣ Neutral—Growth’s cool, risks hover. 3️⃣ Bearish—Hype fades fast. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:CELH ’s Q4 and Alani Nu deal spark a 33% leap—$332M, $1.65B buy 🌍🪙. Resilience shines, but overlap looms—champ or chase?
NASDAQ:CELHLong
by DCAChampion
ETHEREUM’S 2025—$ETH POWERS UP WITH ETFs & DEFIETHEREUM’S 2025— CRYPTOCAP:ETH POWERS UP WITH ETFs & DEFI (1/9) Good morning, Tradingview! Ethereum’s flexing muscle—ETFs and DeFi keep CRYPTOCAP:ETH humming 📈🔥. Institutional cash and altcoin grit shine—let’s unpack this crypto king! 🚀 (2/9) – ETF BUZZ • Inflows: $SEED_TVCODER77_ETHBTCDATA:3B+ into ETH ETFs since July ‘24 💥 • Feb Surge: $500M+ in a week—BlackRock leads 📊 • Outlook: $10-15B by year-end? Big players bet big— CRYPTOCAP:ETH ’s got juice! (3/9) – DEFI DOMINANCE • TVL: $120B locked in Feb ‘25—up from $78B 🌍 • Share: 60%+ of DeFi’s action 🚗 • Goal: $200B by Dec? Steno says maybe 🌟 Ethereum’s the DeFi backbone—unshaken! (4/9) – ALTCOIN EDGE • Altcoin Cap: $1.6T— CRYPTOCAP:ETH holds 10-12% 📈 • ETH/BTC: Climbing to 0.06—alt season whispers • Vs. BTC: 57% dominance— CRYPTOCAP:ETH stands tall Resilient king—altcoins rally behind! 🌍 (5/9) – RISKS ON RADAR • Regs: Rules could snag ETF, DeFi growth ⚠️ • Rivals: Solana bites at CRYPTOCAP:ETH ’s heels 🏛️ • Price Dip: $2,632—off Jan highs 📉 Solid, but not bulletproof—watch out! (6/9) – SWOT: STRENGTHS • ETFs: $ 3B+ inflows—cash keeps flowing 🌟 • DeFi: $120B TVL—ecosystem champ 🔍 • Stake: 54M+ ETH locked—rock steady 🚦 CRYPTOCAP:ETH ’s the muscle in crypto town! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: $ 2,632 lags inflows—sentiment lags 💸 • Opportunities: $ 200B TVL, Pectra lifts 🌍 Can CRYPTOCAP:ETH zap to new heights? (8/9) – CRYPTOCAP:ETH ’s ETF & DeFi run—what’s your vibe? 1️⃣ Bullish—King keeps ruling. 2️⃣ Neutral—Growth’s cool, risks hover. 3️⃣ Bearish—Rivals steal the crown. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY CRYPTOCAP:ETH ’s humming—$ 3B ETFs, $120B DeFi, altcoin grit 🌍. $ 200B TVL in sight, but rivals lurk. Champ or challenger?
BINANCE:ETHUSDLong
by DCAChampion
$US30 DOW JONES—STEADY AMID THE STORMDOW JONES—STEADY AMID THE STORM (1/9) Good morning, Tradingview! The Dow Jones is the cool-headed cousin—less wild than Nasdaq’s growth party 📈🔥. Blue-chip stability shines, even as inflation bites—let’s unpack it! 🚀 (2/9) – WHY SO CALM? • Makeup: 30 big, steady names—Walmart, Goldman 💥 • Price-Weighted: High flyers lead, not tech zingers 📊 • Edge: Less sway from growth stock swings Dow’s the tortoise—slow and steady wins? (3/9) – RECENT VIBES • Feb 22: 1.7% dip—support at 43,400 holds 🌍 • VIX: Stays chill—Nasdaq would’ve freaked 🚗 • CPI Hit: 400-point drop, 300 back—meh 🌟 Stability’s the Dow’s secret sauce! (4/9) – SECTOR SNAP • Vs. Nasdaq: Tech’s jittery—Dow’s diversified 📈 • Volatility: ~15-20% vs. Nasdaq’s 25-30% • Champs: Blue-chips buffer the chaos Steadier ship—less Nasdaq nuttiness! 🌍 (5/9) – INFLATION RIPPLES • CPI Spike: 3% YoY—400-point jolt ⚠️ • Fed: No rush to cut—rates sting 🏛️ • X Buzz: Tariffs, inflation spook recovery 📉 Even the Dow feels the heat—but shrugs! (6/9) – SWOT: STRENGTHS • Stability: Blue-chip backbone holds firm 🌟 • Dividends: Cash flows steady the ship 🔍 • Mix: Less tech tantrums—broad base 🚦 Dow’s the rock in choppy waters! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Inflation nicks costs—ouch 💸 • Opportunities: Safety shines if tech flops 🌍 Can Dow dodge the inflation blues? (8/9) – Dow’s steady play—what’s your vibe? 1️⃣ Bullish—Stability’s golden. 2️⃣ Neutral—Holds, but inflation looms. 3️⃣ Bearish—Growth wins anyway. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY Dow’s less jittery—blue-chips cushion the storm 🌍🪙. Inflation’s a nag, but stability rules. Rock or relic?
ICMARKETS:US30Long
by DCAChampion
SPX Finally Moves, Will 6000 Hold?SPX Finally Moves – But Will 6000 Hold? | SPX Market Analysis 24 Feb 2025 Last week’s market action was like watching a cat decide whether to jump off a shelf—hesitation, commitment, regret, and then chaos. SPX pushed through the bull trigger on Wednesday, only to whip back through the hedge & bear trigger, finally showing some real movement on Friday. But before we get too excited, SPX is still stuck inside a larger range, with 6000 as the next key battleground. Will we see a range breakout or another rejection? Let’s dive in. --- Deeper Dive Analysis: SPX Moves – But Is It Just Another Range Play? Last week gave us plenty of action, but SPX hasn’t truly escaped its larger range yet. 📌 What happened last week? SPX broke the bull trigger on Wednesday 🚀 Immediately flipped back through the hedge & bear trigger 🤦‍♂️ Friday’s move finally opened things up 🔓 Now, we’re eying 6000 as the next decision point. 📌 Two potential setups: ✅ Range Reversal – Price rejects 6000 and moves back inside the range ✅ Breakout Trade – SPX clears 6000, confirming a new leg up Either way, I’ll be watching closely for the next trade setup. VIX Says ‘No Crash… Yet’ 📉 The volatility index (VIX) remains below 20, meaning: No imminent crash signals 🛑 Fear is elevated but not panicking Still room for surprises, but not full-blown chaos (yet!) If VIX jumps past 20 and keeps climbing, then we’ll talk about more extreme downside risk. Overnight Futures – A Small Bounce, But No Turn Yet 🌅 Futures are slightly green, but they don’t confirm: A major bullish turn ❌ A full-blown breakdown ❌ Right now, it’s more noise than signal. What’s Next? 📌 I remain bearish on my income swing trades 📉 📌 Waiting for confirmation—either: Bullish reversal (v-shaped price action shift) 🔄 Bearish breakdown (clean range break below 6000) 🚨 For now, it’s another waiting game—but one that could pay off big when the next major move arrives. --- Fun Fact 📢 Did you know? In 2010, the Flash Crash wiped out nearly $1 trillion in market value in just 36 minutes, only to recover almost entirely by the end of the day. The culprit? A single trader’s algorithm running wild. 💡 The Lesson? Sometimes, market chaos isn’t about fundamentals—it’s just a rogue algorithm losing its mind.
SP:SPXShort
by MrPhilNewton
2
EURO LIFTS POST-GERMAN VOTE—BUT USD BITES BACKEURO LIFTS POST-GERMAN VOTE—BUT USD BITES BACK FX:EURUSD (1/9) Good morning, Tradingview Fam! Germany’s election—Merz and CDU on top—gave the euro a quick jolt, up 0.44% to $1.0507 📈🔥. Markets dig the stability vibe, but it’s fading fast—let’s unpack this tussle! 🚀 (2/9) – ELECTION SPARK • Euro Bump: Hit $1.0530 overnight—election cheer 💥 • Markets: DAX futures up 1.2%, EUROSTOXX 50 +0.66% 📊 • Fade: Now at $1.0480—USD’s flexing back Brief lift—stability’s sweet, but not sticky! (3/9) – TECH TELLTALE • Resistance: $1.0500-1.0510 wall holds firm 🌍 • Support: $1.0470 pivot, then $1.0440 if it slips 🚗 • Charts: Double top whispers at $1.0530 🌟 Traders on X see a retreat—bearish juice brewing? (4/9) – USD PUSHBACK • Jobless Claims: Weak last week, USD softened a tad 📉 • Fed: No rush to cut—rates steady, Nvidia looms • Muscle: Dollar’s clawing back—ballast holds AMEX:USD ’s got grit—euro’s nudge ain’t enough! 🌍 (5/9) – RISKS IN PLAY • Volatility: PMI data, Nvidia earnings stir the pot ⚠️ • Sentiment: X split—liquidity grab or bear turn? 🏛️ • Levels: Below $1.0470 opens $1.0390 risk 📉 Quick sprint—can euro keep the pace? (6/9) – SWOT: STRENGTHS • Election Lift: CDU win sparks euro hope 🌟 • Markets: European futures pop—optimism flows 🔍 • Cash: $1.0530 peak shows buyer guts 🚦 Euro’s got some spark—briefly lit! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: $1.0510 cap, USD fights back 💸 • Opportunities: PMI beats could push $1.0600 🌍 Will euro dodge the dollar’s jab? (8/9) – Euro’s election bump—what’s your call? 1️⃣ Bullish—Stability wins out. 2️⃣ Neutral—Blip, not a trend. 3️⃣ Bearish—USD takes the ring. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY Euro spiked to $1.0507 on Germany’s vote—CDU’s steady hand 🌍🪙. Now $1.0480—USD’s got claws. Resistance bites, downside looms—blip or bust?
by DCAChampion
S&P 500 Daily Chart Analysis For Week of Feb 21, 2025Technical Analysis and Outlook: In the most recent weekly trading session, the S&P 500 surpassed our completed Outer Index Rally threshold of 6120, rendering the Key Resistance at this level obsolete. Nevertheless, following a significant price reversal, the index breached the Mean Support level of 6049 and is approaching the critical support level established at 5995. The index could decline further, potentially reaching the Mean Support level of 5939 and the Key Support at 5827. Should the index initiate an upward movement from its current position or the Mean Support level of 5995, it may ascend to the newly established Mean Resistance level of 6082, potentially extending toward the Key Resistance level of 6143.
SP:SPX
by TradeSelecter
EUR/USD Daily Chart Analysis For Week of Feb 21, 2025Technical Analysis and Outlook: This week, the Euro reapproached our designated Mean Resistance level of 1.050 and reversed its upward momentum. This trend indicates a continuation of the downward price movement, establishing a new support level marked at 1.042. Further declines may materialize, with potential targets including Mean Support at 1.030, a weaker Key Support at 1.024, the completed Outer Currency Dip at 1.020, and the outermost target Outer Currency Dip at 1.005. Contrariwise, should the anticipated downward correction not transpire, the Eurodollar may experience an upward rally, possibly revisiting the Mean Resistance level of 1.050 and subsequently engaging with the Inner Currency Rally target of 1.060.
by TradeSelecter
Bitcoin(BTC/USD) Daily Chart Analysis For Week of Feb 21, 2025Technical Analysis and Outlook: During last week's trading session, Bitcoin was unable to reach our designated Mean Resistance level at 101300 and has remained stagnant near the Mean Support at 95700. This trend indicates a potential continuation of the pullback, which may cross-check the Mean Support level at 95700, with the prospect of further decline toward the Outer Coin Dip identified at 89000 via additional Mean Support levels at 94400, and 92500. Conversely, should the anticipated pullback not materialize, Bitcoin may experience upward momentum, thereby testing the newly established Mean Resistance level at 98300. This development could facilitate an extension toward 101500 and beyond.
BITSTAMP:BTCUSD
by TradeSelecter
SOLID BIOSCIENCES—$SLDB CASHES UP FOR GENE THERAPY PUSHSOLID BIOSCIENCES— NASDAQ:SLDB CASHES UP FOR GENE THERAPY PUSH (1/9) Good afternoon, Tradingview! Solid Biosciences is stacking cash—no revenue yet, but a $200M raise has tongues wagging 📈🔥. NASDAQ:SLDB ’s betting big on gene therapy—here’s the scoop! 🚀 (2/9) – CASH, NOT SALES • Revenue: Zilch—clinical-stage vibes 💥 • Q3 ‘24 Loss: $0.61/share, missed $0.58 est. 📊 • Cash Boost: $200M offering just landed No sales, but NASDAQ:SLDB ’s war chest is growing! (3/9) – BIG MOVE • Feb 18 Raise: $200M via 35.7M shares, warrants 🌍 • Cash Pile: Was $171M, now nearing $350M 🚗 • Goal: Fuel SGT-003 trials into ‘27 🌟 NASDAQ:SLDB ’s loading up for the long haul! (4/9) – SECTOR CHECK • Market Cap: $500M post-raise 📈 • Vs. Peers: Sarepta’s 13B dwarfs it—revenue rules • Edge: Low EV ($150M), big therapy dreams Undervalued biotech bet or long shot? 🌍 (5/9) – RISKS ON DECK • Trials: SGT-003 flops could sink it ⚠️ • Sentiment: 30% drop from Jan peak—jitters 🏛️ • Burn: $20-25M/quarter—clock’s ticking 📉 High stakes, high risks—can it deliver? (6/9) – SWOT: STRENGTHS • Cash: $200M raise powers trials 🌟 • SGT-003: Early data dazzles, Fast Track nod 🔍 • DMD Focus: Huge need, blockbuster shot 🚦 NASDAQ:SLDB ’s got fuel and firepower! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: No revenue, all-in on one play 💸 • Opportunities: $2-4B cap if trials pop 🌍 Can NASDAQ:SLDB turn cash into a cure? (8/9) – NASDAQ:SLDB ’s $200M haul—your take? 1️⃣ Bullish—Gene therapy gold ahead. 2️⃣ Neutral—Wait for trial proof. 3️⃣ Bearish—Risks outweigh the buzz. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:SLDB ’s revenue-free, but $200M keeps SGT-003 alive—stock’s buzzing 🌍🪙. Low EV vs. peers, yet trials and rivals loom. Cure or bust?
NASDAQ:SLDBLong
by DCAChampion
zkSync Fresh L2 coin for ETH. 458 million $ investment by fundsLogarithm. Time frame 1 day. Since the coin is fresh (people sell freebies), and it was recently listed, if the market will be dominated by a downtrend until October, a downtrend channel will be formed in case of a break of the key support. _____________________________________ Most importantly: 1️⃣ There was aerdrop manipulation , the community got a very small % of the promised coins, which is in the hands of developers and crypto funds (after shaking out now, there will be full control over the price). 2️⃣ It is worth noting that crypto funds “invested” (with speculative interest) 458 million dollars in the asset. Which is an absolute record. The first and second are extremely positive for the maximum prices of the asset in the cycle in the future. Consequently, the asset is interesting for investment and position trading, and it does not matter what will happen now locally for a couple of months. Work from the average buy/sell price. ____________________________________ The chart shows the key resistance levels for the first significant pumping after the trend break, as well as the maximum distribution zone targets of this cycle. The price potential will be “unlocked” similarly naturally not now, but when the solution will be implemented, there will be media PR, smart money will partially “exit” from the asset. The potential is naturally great, it is shown, who is attentive. Let me remind you, L2 is a solution for scaling the ETH network. When this is implemented and PR'd and ETH is in its first distribution zone, then pump in similar small capitalization assets. __________________________________ Work from the average price of purchases , so in the future sales and no minimums and maximums (even if you are sure that you know and understand how “exactly” it will be, I note that most people who do everything by reverse think so), as this is the fate of true hamsters. At the same time, you need to understand the zones where it is cheap and where it is expensive, and what the general trend in the market is developing. ⏰ Profit from the local game (not necessarily to work this way) is not big (you “spin the volume” part of the allocated money to a certain zone of the asset - work). But, such local work gives you to overcome fear, because you always have money to increase coins. ⚠️ Do not abuse stop loss , where it is not necessary, because everything will be taken away on the “flat place”. ⚠️ Prefer spot trading , which forgives elementary mistakes, if you are not a very good trader. With margin and futures, your risk must be justified. If you are a ludomaniac (most sick people won't admit it, maybe you are one/one of them) then leave this high risk trading. 🐹 Psychology . If, you feel that you, like everyone else, will do, when not necessary under psychological pressure and news some not logical bullshit, it is better not to trade at all, and invest. “Hold” coins for a couple months, dividing the amount of the entry into 2-3 parts. When the market is distributed, you will sell with a big profit. Maximum targets (not necessarily, as depends on a lot of factors), is the zone 0,6 - 1 dollar.
by SpartaBTC
4
Buy the Dip: TEM is a Resilient AI Healthcare Pick for 2025Tempus AI NASDAQ:TEM is presenting a compelling investment opportunity as we move into 2025. This health tech company, focused on leveraging AI for precision medicine, has weathered a recent downturn and is showing strong signs of recovery. After a 4 week correction that presented a chance to buy at a discount, TEM has finally shown the ability to rally. This recovery makes it a particularly interesting prospect for several reasons: 1. AI's Continued Rise: The field of artificial intelligence is advancing at breakneck speed, and Tempus is at the forefront of applying these advancements to healthcare. Their work in areas like genomic sequencing and data analysis for personalized treatment plans positions them exceptionally well to capitalize on this megatrend. 2. Weathering the Political Storm: Tempus's core business is less vulnerable to possible tariffs that may be introduced by incoming President Trump. Healthcare, particularly innovative approaches to disease treatment, remains a critical sector regardless of the political landscape. Furthermore, Tempus' customers being mostly internal U.S. customers provides further resilience in the face of possible tariffs. 3. Technical Rebound: As the attached chart illustrates, TEM is in the midst of a technical bounce back. The recent price action suggests that the sell-off may be overdone, and the stock is finding support at current levels. The upward sloping support and resistance lines indicate a potential 40-80% gain if TEM can continue to show resilience in the face of selling pressure. The stock currently trades below it's 20 day EMA, but the recent rally shows that it could potentially find support along this average before continuing to trend upwards. In Conclusion: Tempus AI offers a unique combination of growth potential in a rapidly expanding sector, resilience to potential political headwinds, and a technically attractive entry point. While all investments carry risk, TEM's current profile suggests it's a stock worth serious consideration for gaining exposure to the intersection of AI and healthcare in 2025, especially at these highly discounted prices. Disclaimer: This is not financial advice. Conduct your own research before making any investment decisions. Remember, Patience is Paramount.
NASDAQ:TEMLong
by PatienceIsParamount
U.S. FIRMS SWAP DOLLARS FOR EURO to lower funding costsU.S. FIRMS SWAP DOLLARS FOR EURO to lower funding costs—SMART MOVE? (1/9) Good afternoon, Tradingview! U.S. companies are flipping dollar debt into euros—slashing borrowing costs 📈🔥. Cross-currency swaps are the hot ticket amid rate gaps. Let’s break it down! 🚀 (2/9) – SWAP SURGE • Trend: Dollar bonds morph into euros 💥 • Why: Eurozone rates lag U.S. by ~200 points 📊 • Volume: $266B in Jan ‘25 swaps, up 7% YoY Lower rates, big savings—companies pounce! (3/9) – THE TRIGGER • Fed: Holds steady—U.S. rates stay high 🌍 • ECB: Eases up—eurozone softens 🚗 • Trump Tariffs: Stir inflation fears—volatility spikes 🌟 Dollar strength pushes firms to euro deals! (4/9) – HOW IT WORKS • Swap: Trade dollar debt for euro payments 📈 • Gain: Cheaper interest, currency hedge • Impact: Millions saved, euro cash flows shine It’s a financial jujitsu move—clever stuff! 🌍 (5/9) – RISKS IN PLAY • Euro Flip: Stronger euro could zap savings ⚠️ • FX Losses: Hedging costs climb if dollar dips 🏛️ • Uncertainty: Fed vs. ECB—rate dance wobbles 📉 Smart bet, but not risk-free! (6/9) – WHY NOW? • Rate Gap: U.S. high, eurozone low—carry’s juicy 🌟 • Trump Effect: Tariffs fuel dollar power 🔍 • Global Ops: U.S. firms shield Europe earnings 🚦 Timing’s ripe—swaps are the shield! (7/9) – MARKET VIBE • Early ‘25: Swap restructures cash in 🌍 • Savings: redirected to debt, flexibility 📈 • Trend Watch: Grows if rate split holds Companies adapt—financial acrobatics in action! (8/9) – Dollar-to-euro swaps—what’s your take? 1️⃣ Bullish—Cost cuts win big. 2️⃣ Neutral—Works now, risks later. 3️⃣ Bearish—Euro rebound kills it. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY U.S. firms swap dollars for euros—saving millions as rates diverge 🌍🪙. Tariffs and Fed fuel the play, but euro risks lurk. Genius or gamble?
TVC:US10Y
by DCAChampion
$TKA THYSSENKRUPP & IVECO—HIDDEN DEFENCE GEMS SHINEXETR:TKA THYSSENKRUPP & IVECO—HIDDEN DEFENCE GEMS SHINE (1/9) Good afternoon, Tradingview! Thyssenkrupp’s stock soared 20% this week—defence spending’s the buzz 📈🔥. Investors eye TKMS and Iveco’s IDV as undervalued stars. Let’s unpack this rally! 🚀 (2/9) – MARKET SURGE • Thyssenkrupp: 20% spike Monday, 53% YTD 💥 • Iveco: 68% YTD—IDV’s 10% margin shines 📊 • Driver: Europe’s military budget boom Defence cash is flipping the script—big gains! (3/9) – DEFENCE PLAYS • TKMS Spin-Off: Warship unit set for ‘25 🌍 • Iveco IDV: Defence arm spins out in ‘25 🚗 • BofA: TKMS worth half Thyssenkrupp’s cap 🌟 Hidden gems catching the spotlight! (4/9) – SECTOR SNAPSHOT • Defence P/E: 25.8x vs. 18x 3 yrs ago 📈 • Thyssenkrupp & Iveco: ~8x—bargains? • Vs. Giants: Rheinmetall, BAE soar, but these lag Value hunt’s on—undervalued or overhyped? 🌍 (5/9) – RISKS TO WATCH • Peace Talks: Ukraine deal softens demand? ⚠️ • Execution: Spin-offs need to deliver 🏛️ • Focus: Beyond big defence names risky 📉 Rally’s hot—can it hold the heat? (6/9) – SWOT: STRENGTHS • Thyssenkrupp: €16B+ TKMS backlog 🌟 • Iveco: IDV’s 10% profit margin 🔍 • Cash Flow: Thyssenkrupp hits €0-300M ‘25 🚦 Defence muscle’s flexing hard! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Thyssenkrupp’s steel drag, Iveco’s focus 💸 • Opportunities: EU budget hikes, spin-off buzz 🌍 Can these sleeper hits wake up big? (8/9) –Thyssenkrupp & Iveco defence bets—your call? 1️⃣ Bullish—Spin-offs spark a surge. 2️⃣ Neutral—Growth’s there, risks balance. 3️⃣ Bearish—Rally fades fast. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY Thyssenkrupp’s 20% leap, Iveco’s IDV glow—defence cash ignites hidden plays 🌍🪙. Cheap vs. giants, but risks lurk. Gems or mirage?
XETR:TKALong
by DCAChampion